Corticosteroids in COVID-19: one size does not fit all
- PMID: 33574071
- PMCID: PMC7877324
- DOI: 10.1183/13993003.00224-2021
Corticosteroids in COVID-19: one size does not fit all
Abstract
Organising pneumonia and acute fibrinous and organising pneumonia have been reported as the predominant patterns in pathological samples from COVID-19 patients. Critically ill COVID-19 patients may benefit even more from higher corticosteroid doses.
Conflict of interest statement
Conflicts of interest: A. Gogali has nothing to disclose. Conflicts of interest: C. Kyriakopoulos has nothing to disclose. Conflicts of interest: K. Kostikas has nothing to disclose.
Comment on
-
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.Eur Respir J. 2020 Dec 24;56(6):2002808. doi: 10.1183/13993003.02808-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 32943404 Free PMC article. Clinical Trial.
References
-
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group , Sterne JAC, Murthy S, et al. . Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA 2020; 324: 1330–1341. doi:10.1001/jama.2020.17023 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical